Inhibition of oxidative stress in atrial fibrillation
AssigneeNorthwestern University
InventorRishi Arora
Life of this patent
Estimating the term…
Abstract
Disclosed herein are pharmaceutical compositions and methods for inhibiting oxidative stress in a subject having atrial or ventricular arrhythmias, ventricular failure or heart failure. The methods include administering an effective amount of a NOX2 inhibitor agent to the subject, wherein said administering is under conditions such that a level of oxidative stress in myocardial tissue is reduced or eliminated. The pharmaceutical compositions include a NOX2 inhibitor agent.
Claims16
A method of inhibiting oxidative stress in a subject having atrial fibrillation (AF), comprising administering directly in atrial myocardial tissue of the subject having atrial fibrillation (AF) an effective amount of a NADPH oxidase 2 (NOX2) inhibitor agent, wherein the NOX2 inhibitor agent comprises a NOX2 shRNA and wherein said administering is under conditions such that a level of oxidative stress in atrial myocardial tissue of the subject is reduced or eliminated.
A method of treating a subject having atrial fibrillation (AF), comprising administering directly in atrial myocardial tissue of the subject having atrial fibrillation (AF) an effective amount of a NADPH oxidase 2 (NOX2) inhibitor agent, wherein the NOX2 inhibitor agent comprises a NOX2 shRNA and wherein said administering is under conditions such that a level of atrial fibrillation (AF) is reduced or eliminated.
Dependencies are inferred from the claim text.